Erythromycin (Oral) interactions
Full monograph for Erythromycin (Oral)Check it against another medicine
Medicines
722 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acalabrutinib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized… | 2 sources — open the full entry |
| Alfuzosin Hydrochloride | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of alfuzosin, which is primarily metabolized by the… | 8 sources — open the full entry |
| Amiodarone Hydrochloride | Major | Metabolism · Synergy | Amiodarone can cause dose-related prolongation of the QT interval. Coadministration with other agents that can prolong the QT interval such as macrolide… | 10 sources — open the full entry |
| Amisulpride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Major | Metabolism | Some macrolide antibiotics inhibit CYP450 3A4 and may elevate the plasma concentrations of HMG-CoA reductase inhibitors that are metabolized by the isoenzyme…2 documented mechanisms | 43 sources — open the full entry |
| Arsenic Trioxide | Major | Synergy | Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the… | 4 sources — open the full entry |
| Artemether + Lumefantrine | Major | Metabolism · Synergy | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized…3 documented mechanisms | 13 sources — open the full entry |
| Atorvastatin + Ezetimibe | Major | Metabolism · Unknown | Some macrolide antibiotics inhibit CYP450 3A4 and may elevate the plasma concentrations of HMG-CoA reductase inhibitors that are metabolized by the isoenzyme…2 documented mechanisms | 38 sources — open the full entry |
| Atorvastatin Calcium | Major | Metabolism | Some macrolide antibiotics inhibit CYP450 3A4 and may elevate the plasma concentrations of HMG-CoA reductase inhibitors that are metabolized by the isoenzyme… | 38 sources — open the full entry |
| Avanafil | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme. | 6 sources — open the full entry |
| Axitinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the… | 7 sources — open the full entry |
| Betrixaban | Major | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the plasma concentrations of betrixaban, which is a substrate of the… | 11 sources — open the full entry |
| Brexpiprazole | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these… | 5 sources — open the full entry |
| Brigatinib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of brigatinib, which is partially metabolized by… | 4 sources — open the full entry |
| Cabergoline | Major | Metabolism | Coadministration with certain macrolide antibiotics may significantly increase the plasma concentrations of ergot derivatives. The mechanism is macrolide… | 48 sources — open the full entry |
| Cabozantinib | Major | Synergy | Cabozantinib can cause prolongation of the QT interval. | 7 sources — open the full entry |
| Carbamazepine | Major | Metabolism | Some macrolide antibiotics can significantly increase serum carbamazepine levels. The mechanism is probably inhibition of hepatic CYP450 3A4 isoenzymes. Severe… | 22 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of erythromycin, which is primarily metabolized by the isoenzyme… | 11 sources — open the full entry |
| Chloroquine Phosphate | Major | Synergy | Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong… | 22 sources — open the full entry |
| Cilostazol | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active… | 12 sources — open the full entry |
| Citalopram Hydrobromide | Major | Synergy | Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 15 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of erythromycin, which is primarily metabolized by the isoenzyme… | 11 sources — open the full entry |
| Colchicine | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may significantly increase the serum concentrations of colchicine, which is primarily metabolized by the… | 36 sources — open the full entry |
| Crizotinib | Major | Synergy | Crizotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT… | 6 sources — open the full entry |
| Cyclosporine (Oral) | Major | Metabolism | Coadministration with macrolide antibiotics that are potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which… | 37 sources — open the full entry |
| Dasatinib | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by… | 8 sources — open the full entry |
| Deflazacort | Major | Metabolism | Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of 21-desdeflazacort, the active… | 3 sources — open the full entry |
| Diltiazem Hydrochloride | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of erythromycin, which is primarily metabolized by the isoenzyme… | 11 sources — open the full entry |
| Docetaxel Trihydrate | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may significantly increase the plasma… | 21 sources — open the full entry |
| Efavirenz | Major | Metabolism | Efavirenz can cause significant QT interval prolongation in patients with the CYP450 2B6 *6/*6 genotype due to reduced metabolic clearance of the drug stemming… | 6 sources — open the full entry |
| Elacestrant | Major | Metabolism | Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elacestrant, which is primarily… | 1 sources — open the full entry |
| Eplerenone | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme. | 1 sources — open the full entry |
| Ergometrine Maleate | Major | Metabolism | Coadministration with certain macrolide antibiotics may significantly increase the plasma concentrations of ergot derivatives. The mechanism is macrolide… | 48 sources — open the full entry |
| Escitalopram Oxalate | Major | Synergy | Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 13 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism · Others | Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of erythromycin, which is primarily metabolized by the isoenzyme…2 documented mechanisms | 14 sources — open the full entry |
| Everolimus | Major | Absorption · Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 and P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral… | 2 sources — open the full entry |
| Fentanyl Citrate | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fentanyl, which is primarily metabolized by the isoenzyme. Increased… | 12 sources — open the full entry |
| Finerenone | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Flibanserin | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| FluconazolebaseOphthalmic | Major | Metabolism · Synergy | Coadministration with fluconazole may increase the plasma concentrations of erythromycin. The proposed mechanism is fluconazole inhibition of the CYP450… | 11 sources — open the full entry |
| Fluvastatin | Major | Metabolism | Severe myopathy and rhabdomyolysis have been reported with concomitant use of HMG-CoA reductase inhibitors and erythromycin in severely ill patients. The… | 9 sources — open the full entry |
| Gatifloxacin | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Metabolism · Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…2 documented mechanisms | 58 sources — open the full entry |
| Haloperidol | Major | Synergy | Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 14 sources — open the full entry |
| Hydroxychloroquine Sulphate | Major | Synergy | Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong… | 22 sources — open the full entry |
| Ibrutinib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ibrutinib, which is primarily metabolized by… | 6 sources — open the full entry |
| Iloperidone | Major | Synergy | Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 9 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of erythromycin, which is primarily metabolized by the isoenzyme… | 11 sources — open the full entry |
| Ivabradine | Major | Metabolism · Synergy | Coadministration with moderate inhibitors of CYP450 3A4 such as erythromycin may significantly increase the plasma concentrations of ivabradine, which is… | 13 sources — open the full entry |
| Ivosidenib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivosidenib, which is primarily metabolized by… | 5 sources — open the full entry |
Food & lifestyle
grapefruit juice
ModerateMetabolism
Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin. The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion. Grapefruit juice may increase the plasma concentrations of orally administered erythromycin. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.
What to do: In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals. However, some erythromycin products may be taken without regard to meals.
7 sources
- Welling PG, Huang H, Hewitt PF, Lyons LL "Bioavailability of erythromycin stearate: influence of food and fluid volume." J Pharm Sci 67 (1978): 764-6
- Welling PG, Elliott RL, Pitterle ME, et al. "Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate." J Pharm Sci 68 (1979): 150-5
- Welling PG "Influence of food and diet on gastrointestinal drug absorption: a review." J Pharmacokinet Biopharm 5 (1977): 291-334
- Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC "Bioavailability of erythromycin ethylsuccinate in pediatric patients." J Clin Pharmacol 18 (1978): 194-202
- Malmborg AS "Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base." J Antimicrob Chemother 5 (1979): 591-9
- Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW "Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation." J Clin Pharmacol 29 (1989): 79-84
- Kanazawa S, Ohkubo T, Sugawara K "The effects of grapefruit juice on the pharmacokinetics of erythromycin." Eur J Clin Pharmacol 56 (2001): 799-803
alcohol
MinorAbsorption
Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic. The mechanism appears to be due to slowed gastric emptying by ethanol.
What to do: Patients should be advised to avoid ethanol while taking erythromycin salts.
1 source
- Morasso MI, Chavez J, Gai MN, Arancibia A "Influence of alcohol consumption on erythromycin ethylsuccinate kinetics." Int J Clin Pharmacol 28 (1990): 426-9
Therapeutic duplication
Drug classes that overlap with Erythromycin (Oral), so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
macrolide-type antibiotics
The recommended maximum number of medicines in the 'macrolide-type antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'macrolide-type antibiotics' category.
Example product in the source data (US market): Prevpac
macrolide-type antibiotics
The recommended maximum number of medicines in the 'macrolide-type antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'macrolide-type antibiotics' category.
Example product in the source data (US market): Amoxicillin/clarithromycin/omeprazole
macrolide-type antibiotics
The recommended maximum number of medicines in the 'macrolide-type antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'macrolide-type antibiotics' category.
Example product in the source data (US market): Voquezna triple pak